SLC6A3 and colorectal adenocarcinoma: SLC6A3 is a well-known dopamine transporter, and studies indicate that SLC6A3 expression changes in kidney and colorectal adenocarcinomas may be a marker of cancer malignancy and that SLC6A3 gene changes affect cancer prognosis [88,89,90].